114 related articles for article (PubMed ID: 25967674)
1. Prevalence of the UGT1A1*6 (c.211G>A) Polymorphism and Prediction of Irinotecan Toxicity in Iranian Populations of Different Ethnicities.
Shakibi R; Kamalidehghan B; Ahmadipour F; Meng GY; Houshmand M
Chemotherapy; 2014; 60(5-6):279-87. PubMed ID: 25967674
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities.
Bagheri A; Kamalidehghan B; Haghshenas M; Azadfar P; Akbari L; Sangtarash MH; Vejdandoust F; Ahmadipour F; Meng GY; Houshmand M
Drug Des Devel Ther; 2015; 9():2627-34. PubMed ID: 25999696
[TBL] [Abstract][Full Text] [Related]
3. [Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction].
Onoue M; Inui K
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1080-5. PubMed ID: 18633245
[TBL] [Abstract][Full Text] [Related]
4. [UGT1A1 Genotyping for Proper Use of Irinotecan].
Matsuoka A; Ando Y
Rinsho Byori; 2015 Jul; 63(7):876-82. PubMed ID: 26591441
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia.
Teh LK; Hashim H; Zakaria ZA; Salleh MZ
Indian J Med Res; 2012 Aug; 136(2):249-59. PubMed ID: 22960892
[TBL] [Abstract][Full Text] [Related]
6. UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
Bandyopadhyay A; Sharma S; Behera D; Singh N
Oncologist; 2021 Aug; 26(8):701-713. PubMed ID: 33728696
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of the rs7903146C>T polymorphism in TCF7L2 gene for prediction of type 2 diabetes risk among Iranians of different ethnicities.
Allahdini M; Kamalidehghan B; Akbari L; Azadfar P; Rahmani A; Ahmadipour F; Meng GY; Masserrat A; Houshmand M
Drug Des Devel Ther; 2015; 9():5835-41. PubMed ID: 26604685
[TBL] [Abstract][Full Text] [Related]
8. Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.
Hasegawa Y; Ando Y; Shimokata K
Expert Rev Mol Diagn; 2006 Jul; 6(4):527-33. PubMed ID: 16824027
[TBL] [Abstract][Full Text] [Related]
9. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
10. Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations.
Zhang A; Xing Q; Qin S; Du J; Wang L; Yu L; Li X; Xu L; Xu M; Feng G; He L
Pharmacogenomics J; 2007 Oct; 7(5):333-8. PubMed ID: 17060921
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
[TBL] [Abstract][Full Text] [Related]
12. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
Schulz C; Boeck S; Heinemann V; Stemmler HJ
Anticancer Drugs; 2009 Nov; 20(10):867-79. PubMed ID: 19770637
[TBL] [Abstract][Full Text] [Related]
13. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
[TBL] [Abstract][Full Text] [Related]
14. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
Ferraldeschi R; Minchell LJ; Roberts SA; Tobi S; Hadfield KD; Blackhall FH; Mullamitha S; Wilson G; Valle J; Saunders M; Newman WG
Pharmacogenomics; 2009 May; 10(5):733-9. PubMed ID: 19450125
[TBL] [Abstract][Full Text] [Related]
15. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.
Côté JF; Kirzin S; Kramar A; Mosnier JF; Diebold MD; Soubeyran I; Thirouard AS; Selves J; Laurent-Puig P; Ychou M
Clin Cancer Res; 2007 Jun; 13(11):3269-75. PubMed ID: 17510208
[TBL] [Abstract][Full Text] [Related]
16. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
Toffoli G; Cecchin E; Corona G; Russo A; Buonadonna A; D'Andrea M; Pasetto LM; Pessa S; Errante D; De Pangher V; Giusto M; Medici M; Gaion F; Sandri P; Galligioni E; Bonura S; Boccalon M; Biason P; Frustaci S
J Clin Oncol; 2006 Jul; 24(19):3061-8. PubMed ID: 16809730
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (‑806 C>T) alleles among an Iranian population of different ethnicities.
Dehbozorgi M; Kamalidehghan B; Hosseini I; Dehghanfard Z; Sangtarash MH; Firoozi M; Ahmadipour F; Meng GY; Houshmand M
Mol Med Rep; 2018 Mar; 17(3):4195-4202. PubMed ID: 29328413
[TBL] [Abstract][Full Text] [Related]
18. UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).
Pacheco PR; Brilhante MJ; Ballart C; Sigalat F; Polena H; Cabral R; Branco CC; Mota-Vieira L
Mol Diagn Ther; 2009; 13(4):261-8. PubMed ID: 19712005
[TBL] [Abstract][Full Text] [Related]
19. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Biason P; Masier S; Toffoli G
J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
[TBL] [Abstract][Full Text] [Related]
20. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Fakih MG; Ross ME; Starostik P
Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]